Audebert 1998.

Methods	Location: France No. of centres: multi centre Recruitment period: December 1990 to March 1993
Participants	Inclusion criteria: < 40 years, stage III‐IV endometriosis, pelvic pain, dysmenorrhoea or dyspareunia Exclusion criteria: > 40 years, hormonal treatment for endometriosis within 3/12 (including OCP, progestins), significant medical illness e.g. liver, heart, renal disease, abnormal PAP smear, pregnancy, surgery for endometriosis within 6/12 No. randomised: 55 No. analysed: 53
Interventions	Gr A (n=28) Pre‐surgery medical treatment with nafarelin nasal 400 uG daily x 6/12 Gr B (n=25) Post‐surgery medical treatment with nafarelin nasal 400 uG daily x 6/12
Outcomes	Pain: dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration AFS scores: global, adhesions, endometriosis Ease of surgery
Notes	Power calculation: NS Funding: Syntex Pharmaceuticals International for supply of Nafarelin, grant for trial
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomised" no details of method of sequence generation provided
Allocation concealment (selection bias)	Unclear risk	not mentioned
Blinding (performance bias and detection bias) All outcomes	Low risk	double blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	all randomised patients included in analysis
Selective reporting (reporting bias)	Low risk	important outcomes ‐ AFS scores, recurrence, surgical difficulty reported
Other bias	Low risk	groups appear comparable at baseline